Microsoft word - gravitas half enrolled release final.doc

Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled

June 30, 2009, San Diego, Calif. -- Accumetrics, Inc. announces that it has reached the
halfway mark (1,600 patients) in the enrollment of its landmark clinical trial, GRAVITAS
(Gauging Responsiveness with A VerifyNow® Assay Impact on Thrombosis And Safety).
The trial is specifically designed to demonstrate the value of providing clinicians with
actionable information for patients who are poor responders to clopidogrel (Plavix®). The
multi-center, placebo controlled trial will determine whether tailored antiplatelet therapy
for poor responders, identified based on the results of the company’s VerifyNow P2Y12
Test, reduces major cardiovascular adverse events (e.g., heart attack, stent thrombosis)
following percutaneous coronary intervention (PCI). Currently the trial is being
conducted at more than 70 sites in the U.S. and Canada, with a total enrollment goal of
approximately 2,800 patients.
“We are thrilled to have reached the halfway point for enrollment in our GRAVITAS trial,”
said Jeff Dahlen, Ph.D, Vice President, Clinical and Regulatory Affairs of Accumetrics,
Inc. “Once complete, GRAVITAS will be the largest multi-center clinical trial that links
testing with personalized medicine and improved patient outcomes. We continue our
commitment to ensuring that the VerifyNow System is shown to be an integral tool in
optimizing the use of antiplatelet therapy.”
About GRAVITAS
The concept of variability in response to antiplatelet therapy has been well established.
Also being demonstrated with increased frequency is the question of whether poor
response to antiplatelet therapy, based on a laboratory test, leads to poor patient
outcomes. However, Accumetrics recognizes the need for a study specifically designed
to demonstrate the value of providing clinicians with actionable information to improve
outcomes for those patients who are poor responders to antiplatelet therapy. As a
result, the GRAVITAS study is the first multi-center, placebo-controlled study to
determine whether tailored antiplatelet therapy based on the results of the company’s
VerifyNow System and P2Y12 Test reduces major cardiovascular adverse events post-
PCI. The trial is being coordinated by Scripps Advanced Clinical Trials.
About Accumetrics (www.accumetrics.com)
Accumetrics is committed to advancing medical understanding of platelet function and
enhancing quality of care for patients receiving antiplatelet therapies by providing
industry-leading and widely accessible diagnostic tests for rapid platelet function
assessment.
Accumetrics’ VerifyNow System is the first rapid and easy to use platform for measuring
an individual’s response to multiple antiplatelet agents. Addressing every major
antiplatelet drug, including EC-cleared product for prasugrel and FDA-cleared products
for aspirin, Plavix, ReoPro®, and Integrilin®, the VerifyNow System provides a valuable
tool to help physicians make informed treatment decisions.
The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc., ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis.
CONTACT:
Jules Abraham
Lippert/Heilshorn & Associates
212-838-3777
[email protected]
Timothy I. Still President and CEO Accumetrics 858-404-8260 [email protected]

Source: http://www.kbpartners.com/docs/GRAVITAS_Half_Enrolled_Release_6-30-09.pdf